Kibria G - Search Results

1

Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H. Adorno-Cruz V, et al. Among authors: kibria g. Cancer Res. 2015 Mar 15;75(6):924-9. doi: 10.1158/0008-5472.CAN-14-3225. Epub 2015 Jan 20. Cancer Res. 2015. PMID: 25604264 Free PMC article. Review.

2

miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway.

Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, Ha N, Kibria G, Huo D, Zheng H, Dalton R, Wang Y, Moskalenko GY, Liu H. Samaeekia R, et al. Among authors: kibria g. Clin Cancer Res. 2017 Feb 15;23(4):1091-1103. doi: 10.1158/1078-0432.CCR-16-0943. Epub 2016 Jul 19. Clin Cancer Res. 2017. PMID: 27435395 Free PMC article.

3

A rapid, automated surface protein profiling of single circulating exosomes in human blood.

Kibria G, Ramos EK, Lee KE, Bedoyan S, Huang S, Samaeekia R, Athman JJ, Harding CV, Lötvall J, Harris L, Thompson CL, Liu H. Kibria G, et al. Sci Rep. 2016 Nov 7;6:36502. doi: 10.1038/srep36502. Sci Rep. 2016. PMID: 27819324 Free PMC article.

4

Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges.

Kibria G, Ramos EK, Wan Y, Gius DR, Liu H. Kibria G, et al. Mol Pharm. 2018 Sep 4;15(9):3625-3633. doi: 10.1021/acs.molpharmaceut.8b00277. Epub 2018 May 30. Mol Pharm. 2018. PMID: 29771531 Free PMC article.

5

Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.

Kibria G, Hatakeyama H, Harashima H. Kibria G, et al. Arch Pharm Res. 2014 Jan;37(1):4-15. doi: 10.1007/s12272-013-0276-2. Epub 2013 Nov 23. Arch Pharm Res. 2014. PMID: 24272889 Review.

6

A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.

Kibria G, Hatakeyama H, Harashima H. Kibria G, et al. Int J Pharm. 2011 Jun 30;412(1-2):106-14. doi: 10.1016/j.ijpharm.2011.03.010. Epub 2011 Mar 15. Int J Pharm. 2011. PMID: 21414394 Free article.

7

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.

Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Kibria G, et al. J Control Release. 2011 Jul 30;153(2):141-8. doi: 10.1016/j.jconrel.2011.03.012. Epub 2011 Apr 5. J Control Release. 2011. PMID: 21447361 Free article.

8

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.

Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H. Takara K, et al. Among authors: kibria g. J Control Release. 2012 Aug 20;162(1):225-32. doi: 10.1016/j.jconrel.2012.06.019. Epub 2012 Jun 20. J Control Release. 2012. PMID: 22728515 Free article.

9

The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.

Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Kibria G, et al. Biomaterials. 2013 Jul;34(22):5617-27. doi: 10.1016/j.biomaterials.2013.03.094. Epub 2013 Apr 24. Biomaterials. 2013. PMID: 23623323 Free article.

10

Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.

Kibria G, Hatakeyama H, Sato Y, Harashima H. Kibria G, et al. Int J Pharm. 2016 Jul 25;509(1-2):178-187. doi: 10.1016/j.ijpharm.2016.05.047. Epub 2016 May 24. Int J Pharm. 2016. PMID: 27234700 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page